<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39444997</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>24</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">0975-1599</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Season>Jul-Sep</Season></PubDate></JournalIssue><Title>Middle East African journal of ophthalmology</Title><ISOAbbreviation>Middle East Afr J Ophthalmol</ISOAbbreviation></Journal><ArticleTitle>Bilateral Acute Iris Transillumination Following Coronavirus Disease 2019 Infection.</ArticleTitle><Pagination><StartPage>185</StartPage><EndPage>187</EndPage><MedlinePgn>185-187</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4103/meajo.meajo_69_24</ELocationID><Abstract><AbstractText>Bilateral acute iris transillumination (BAIT) syndrome is an uncommon disorder marked by sudden dispersion of pigment in the anterior chamber, iris sphincter muscle paralysis, and elevated intraocular pressure. This syndrome has been linked to viral infections and the administration of fluoroquinolones such as moxifloxacin. This study presents a case of a 54-year-old male, otherwise in good health, who developed BAIT syndrome 1 week after experiencing an upper respiratory tract infection that followed a coronavirus disease 2019 (COVID-19) diagnosis. The patient was effectively treated with topical prednisolone acetate and antiglaucoma medications. Further studies are required to investigate the relationship between COVID-19 and BAIT to enhance understanding of its pathophysiology.</AbstractText><CopyrightInformation>Copyright: © 2024 Middle East African Journal of Ophthalmology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Albloushi</LastName><ForeName>Abdulrahman F</ForeName><Initials>AF</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alabdi</LastName><ForeName>Ghada</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elmutawi</LastName><ForeName>Hend</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>India</Country><MedlineTA>Middle East Afr J Ophthalmol</MedlineTA><NlmUniqueID>101521797</NlmUniqueID><ISSNLinking>0974-9233</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9PHQ9Y1OLM</RegistryNumber><NameOfSubstance UI="D011239">Prednisolone</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>8B2807733D</RegistryNumber><NameOfSubstance UI="C009935">prednisolone acetate</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C563184">Glaucoma-Related Pigment Dispersion Syndrome</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007499" MajorTopicYN="N">Iris Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007498" MajorTopicYN="N">Iris</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009798" MajorTopicYN="N">Ocular Hypertension</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011239" MajorTopicYN="N">Prednisolone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007429" MajorTopicYN="N">Intraocular Pressure</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014172" MajorTopicYN="N">Transillumination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005902" MajorTopicYN="N">Glaucoma, Open-Angle</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bilateral acute iris transillumination</Keyword><Keyword MajorTopicYN="N">coronavirus disease 2019</Keyword><Keyword MajorTopicYN="N">iris transillumination</Keyword><Keyword MajorTopicYN="N">pigment dispersion</Keyword></KeywordList><CoiStatement>There are no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>24</Day><Hour>16</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>24</Day><Hour>16</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>24</Day><Hour>4</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39444997</ArticleId><ArticleId IdType="pmc">PMC11495286</ArticleId><ArticleId IdType="doi">10.4103/meajo.meajo_69_24</ArticleId><ArticleId IdType="pii">MEAJO-30-185</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bringas Calvo R, Iglesias Cortiñas D. Acute and bilateral uveitis secondary to moxifloxacin. Arch Soc Esp Oftalmol. 2004;79:357–9.</Citation><ArticleIdList><ArticleId IdType="pubmed">15286907</ArticleId></ArticleIdList></Reference><Reference><Citation>Altan C, Basarir B, Bayraktar S, Tugal-Tutkun I. Bilateral acute depigmentation of iris (BADI) and Bilateral acute iris transillumination (BAIT) following acute COVID-19 infection. Ocul Immunol Inflamm. 2023;31:1163–8.</Citation><ArticleIdList><ArticleId IdType="pubmed">36083696</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulmez Sevim D, Sener H, Evereklioglu C. Bilateral acute iris transillumination and elevated intraocular pressure after COVID-19 infection. J Glaucoma. 2023;32:e56–9.</Citation><ArticleIdList><ArticleId IdType="pubmed">36946913</ArticleId></ArticleIdList></Reference><Reference><Citation>Yüksel M, Özdemir HB, Özdek Ş, Gürelik G. Bilateral acute iris transillumination after COVID-19 pneumonia. Eur J Ophthalmol. 2023;33:P115–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9297069</ArticleId><ArticleId IdType="pubmed">35850544</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazari K, Androudi S, Dardiotis E, Tsironi EE, Papageorgiou E. Bilateral acute iris transillumination syndrome following COVID-19 infection and moxifloxacin use. Clin Exp Optom. 2023 doi:10.1080/08164622.2023.2241033.</Citation><ArticleIdList><ArticleId IdType="pubmed">37674269</ArticleId></ArticleIdList></Reference><Reference><Citation>Yagci BA, Atas F, Kaya M, Arikan G. COVID-19 associated bilateral acute iris transillumination. Ocul Immunol Inflamm. 2021;29:719–21.</Citation><ArticleIdList><ArticleId IdType="pubmed">34124990</ArticleId></ArticleIdList></Reference><Reference><Citation>Comba OB. SARS-CoV-2 virus-induced bilateral acute iris transillumination syndrome: The first case series in literature. Indian J Ophthalmol. 2023;71:660–2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10228954</ArticleId><ArticleId IdType="pubmed">36727383</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>